Navigation Links
Wellmune WGP supplementation alleviates
Date:4/8/2008

SAN DIEGO, CA. April 9, 2008 Wellmune WGP, a natural immune-enhancing ingredient from Biothera, reduced the incidence of fever and eliminated the need for study subjects to miss work or school due to the cold-like symptoms, researchers reported today at the 2008 Experimental Biology annual meeting.

Don Cox, Ph.D., Vice President of Research & Development for Biotheras Healthcare Group, said, This studys results are exciting because they show the potential for Wellmune WGP to naturally enhance the bodys innate immune response to protect against and ameliorate the symptoms of something that every one of us encountersthe common cold. These results are consistent with numerous other immune health studies conducted with our ingredient, and indicate the real-life benefits that Wellmune WGP supplementation can provide.

The research will be presented at the Poster Sessions starting 9:00 am on April 9th by Douglas Kalman, Ph.D., RD, FACN, a Director at Miami Research Associates, which conducted the study for Biothera. An abstract of the study is available at www.biothera.com/healthcare.

The double-blind, placebo-controlled study was conducted during the cold season with 40 healthy subjects, aged 18-65. The subjects were treated daily with either 250mg of Wellmune WGP or a placebo for 90 days. Wellmune WGP is a natural carbohydrate that activates key immune cells, including macrophages and neutrophils, to more quickly recognize and kill foreign challenges. The product engages the bodys natural defenses to promote health, wellness and vitality. In contrast with the placebo group, study participants who received Wellmune WGP daily reported:

  • No incidence of medically verified fever.

  • An increase in general health markers, including physical energy and emotional well-being, as measured by a clinically validated health survey questionnaire (SF-36v-2).

  • No need to take a sick day off of work or school (compared with 1.38 days of work/school missed for the placebo group).

In addition, although there were no differences between groups in the number of colds, at the end of the 12-week test period the Wellmune WGP-supplemented group exhibited significant improvements in Physical Component Summary scores as defined in the SF-36v-2 health survey.


'/>"/>

Contact: Dave Walsh
651-256-4606
Strategic Communications
Source:Eurekalert

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a ... intravenous (IV) therapy, today announced receipt of its ISO 13485 Certification, ... by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early ... "This is an ...
(Date:5/23/2017)... May 23, 2017  Hunova, the first robotic gym for the rehabilitation ... officially launched in Genoa, Italy . The first 30 ... and the USA . The technology was developed and ... by the IIT spin-off Movendo Technology thanks to a 10 million euro ... Release, please click: ...
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... At its ... announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of ... been selected for membership in ARCS Alumni Hall of Fame . ASTER ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit ... 7th and 8th June 2018 in San Francisco, CA. The Summit brings together current ... several distinguished CEOs, board directors and government officials from around the world to address ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
Breaking Biology Technology: